Related Experiment Video
Updated: Dec 29, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Familial hypercholesterolemia: Detect, treat, and ask about family
Nishant P Shah1, Haitham M Ahmed2, W H Wilson Tang3
1Duke Heart Center; Assistant Professor of Medicine in Cardiology, Duke University School of Medicine, Durham, NC nishant.shah@duke.edu.
Insights
Familial hypercholesterolemia is a genetic disorder causing high LDL cholesterol due to gene mutations. This significantly increases the risk of early-onset cardiovascular disease, leading to severe health issues and mortality.
Area of Science:
- Genetics
- Metabolic Disorders
- Cardiovascular Science
Background:
- Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder.
- It is characterized by impaired metabolism of low-density lipoprotein cholesterol (LDL-C).
- Mutations in genes such as LDL receptor (LDLR), apolipoprotein B (APOB), and PCSK9 are implicated.
Purpose of the Study:
- To summarize the genetic basis of Familial hypercholesterolemia.
- To highlight the resulting metabolic derangements.
- To underscore the associated cardiovascular risks.
Main Methods:
- Review of genetic mutations affecting LDL-C metabolism.
- Analysis of clinical data on plasma LDL-C levels.
- Epidemiological assessment of cardiovascular disease risk in FH patients.
Main Results:
- FH is caused by mutations in key genes regulating LDL-C.
- Patients exhibit significantly elevated plasma LDL-C levels.
- This leads to a substantially increased risk of premature atherosclerotic cardiovascular disease.
Conclusions:
- FH is a serious inherited condition with severe health consequences.
- Early identification and management are crucial.
- Genetic factors play a pivotal role in cardiovascular disease development.
Abstract:
Familial hypercholesterolemia is an autosomal dominant disorder that affects the metabolism of low-density lipo-protein cholesterol (LDL-C) through mutations in the gene for LDL receptor (LDLR), and less commonly in those for apolipoprotein B (APOB), proprotein convertase subtili-sin-kexin type 9 (PCSK9), and others. Patients with these mutations have elevated plasma levels of LDL-C and, as a result, an increased risk of atherosclerotic cardiovascular disease beginning in childhood, leading to significant risk of illness and death.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...

